Find Tafamidis Meglumine manufacturers, exporters & distributors on PharmaCompass

Tafamidis Meglumine

Tafamidis Meglumine

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

24 API Suppliers, 11 USDMF, 4 EU WC, 8 NDC API, 20 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports

INTERMEDIATES

3 Suppliers

3 Suppliers

DOSSIERs // Finished Dosage Formulations

5 Dossiers, 1 FDA Orange Book, 2 Europe, 1 Canada, 1 Listed Dossiers

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 1 Finished Drug Prices

MARKET PLACE

1 APIs, 1 DOSSIERS // FDF

PATENTS

2 US Patents, 2 US Exclusivities

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 16 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

17,815

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

457.00

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Vyndaqel, 951395-08-7, Fx-1006a, Fx1006a, Fx 1006a, Zu7cf08a1a

Molecular Formula

C₂₁H₂₄Cl₂N₂O₈

Molecular Weight

503.3 g/mol

InChI Key

DQJDBUPLRMRBAB-WZTVWXICSA-N

FDA UNII

ZU7CF08A1A

Tafamidis Meglumine is a soft gelatin capsule formulation containing the meglumine salt form of tafamidis, a small molecule and pharmacological chaperone with potential disease-modifying activity. Tafamidis binds to and stabilizes wild-type and variant (V122I) transthyretin (TTR), thereby preventing tetramer dissociation into monomers; this prevents misfolding of the TTR protein and inhibits the formation of TTR amyloid fibrils and the subsequent deposition of these insoluble protein clusters in peripheral nerve tissues and organs. TTR is a 127 amino acid transport protein for thyroxine and retinol and is secreted by the liver.

1 2D Structure

Tafamidis Meglumine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol

2.1.2 InChI

InChI=1S/C14H7Cl2NO3.C7H17NO5/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-6H,(H,18,19);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

2.1.3 InChI Key

DQJDBUPLRMRBAB-WZTVWXICSA-N

2.1.4 Canonical SMILES

CNCC(C(C(C(CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl

2.1.5 Isomeric SMILES

CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl

2.2 Other Identifiers

2.2.1 UNII

ZU7CF08A1A

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Fx 1006a

2. Fx-1006a

3. Fx1006a

4. Tafamidis

5. Vyndamax

6. Vyndaqel

2.3.2 Depositor-Supplied Synonyms

1. Vyndaqel

2. 951395-08-7

3. Fx-1006a

4. Fx1006a

5. Fx 1006a

6. Zu7cf08a1a

7. Chebi:79345

8. 951395-08-7 (meglumine)

9. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate

10. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic Acid

11. Unii-zu7cf08a1a

12. Tafamidis Meglumine [usan]

13. Tafamidis Meglumine [usan:inn]

14. Vyndaqel (tn)

15. Chembl2105675

16. Schembl14783506

17. Tafamidis Meglumine [mi]

18. Tafamidis Meglumine (jan/usan)

19. Dtxsid50915094

20. Tafamidis Meglumine [jan]

21. Ex-a3550

22. Hy-14852a

23. Mfcd28502032

24. Tafamidis Meglumine [who-dd]

25. Akos037649321

26. At18247

27. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate

28. Tafamidis Meglumine [orange Book]

29. Bs-18043

30. Cs-0045567

31. Pf-06291826

32. D09674

33. Q27148396

34. 1-deoxy-1-(methylazaniumyl)-d-glucitol 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylate

35. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)-d-glucitol (1/1)

36. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)hexitol (1/1)

37. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol

38. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)

39. D-gluco-2,3,4,5,6-pentahydroxy-n-methylhexan-1-aminium 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylate

2.4 Create Date

2008-10-20

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₂₄Cl₂N₂O₈
Molecular Weight	503.3 g/mol
Hydrogen Bond Donor Count	7
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	8
Exact Mass	502.0909711 g/mol
Monoisotopic Mass	502.0909711 g/mol
Topological Polar Surface Area	177 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	506
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in amyloidosis.

Neuropathic heredofamilial amyloidosis

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

Fx-1006A is a first-in-class, disease-modifying compound that is designed to inhibit the formation of amyloid deposits by preventing the misfolding and deposition of the transthyretin protein (TTR), which is associated with amyloidosis.